JP2019055949A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019055949A5 JP2019055949A5 JP2018177525A JP2018177525A JP2019055949A5 JP 2019055949 A5 JP2019055949 A5 JP 2019055949A5 JP 2018177525 A JP2018177525 A JP 2018177525A JP 2018177525 A JP2018177525 A JP 2018177525A JP 2019055949 A5 JP2019055949 A5 JP 2019055949A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- monoclonal antibody
- functional fragment
- plasmin
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 23
- 239000012634 fragment Substances 0.000 claims 22
- 108010088842 Fibrinolysin Proteins 0.000 claims 16
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 claims 12
- 125000003275 alpha amino acid group Chemical group 0.000 claims 12
- 229940012957 plasmin Drugs 0.000 claims 11
- 101000737793 Homo sapiens Cerebellar degeneration-related antigen 1 Proteins 0.000 claims 6
- 238000003776 cleavage reaction Methods 0.000 claims 4
- 230000007017 scission Effects 0.000 claims 4
- 230000000694 effects Effects 0.000 claims 3
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 claims 2
- 108010014172 Factor V Proteins 0.000 claims 2
- 208000032843 Hemorrhage Diseases 0.000 claims 2
- 108060005987 Kallikrein Proteins 0.000 claims 2
- 102000001399 Kallikrein Human genes 0.000 claims 2
- 108010028275 Leukocyte Elastase Proteins 0.000 claims 2
- 102000016799 Leukocyte elastase Human genes 0.000 claims 2
- 101800004937 Protein C Proteins 0.000 claims 2
- 102100036546 Salivary acidic proline-rich phosphoprotein 1/2 Human genes 0.000 claims 2
- 101800001700 Saposin-D Proteins 0.000 claims 2
- 108090000190 Thrombin Proteins 0.000 claims 2
- 102000004142 Trypsin Human genes 0.000 claims 2
- 229960002684 aminocaproic acid Drugs 0.000 claims 2
- 208000034158 bleeding Diseases 0.000 claims 2
- 230000000740 bleeding effect Effects 0.000 claims 2
- 230000020764 fibrinolysis Effects 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 230000036963 noncompetitive effect Effects 0.000 claims 2
- 229960000856 protein c Drugs 0.000 claims 2
- 239000000758 substrate Substances 0.000 claims 2
- 229960004072 thrombin Drugs 0.000 claims 2
- 230000001567 anti-fibrinolytic effect Effects 0.000 claims 1
- 229940082620 antifibrinolytics Drugs 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762561332P | 2017-09-21 | 2017-09-21 | |
| US62/561,332 | 2017-09-21 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019055949A JP2019055949A (ja) | 2019-04-11 |
| JP2019055949A5 true JP2019055949A5 (enExample) | 2021-10-28 |
| JP6971946B2 JP6971946B2 (ja) | 2021-11-24 |
Family
ID=63678447
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018177525A Active JP6971946B2 (ja) | 2017-09-21 | 2018-09-21 | 反応抑制的抗体による特異的プラスミン不活性化 |
Country Status (3)
| Country | Link |
|---|---|
| US (1) | US11066482B2 (enExample) |
| EP (1) | EP3459974B1 (enExample) |
| JP (1) | JP6971946B2 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20230220112A1 (en) * | 2019-10-28 | 2023-07-13 | Monash University | Antibodies for binding plasmin |
| CA3250857A1 (en) * | 2022-05-04 | 2023-11-09 | Univ Bonn Rheinische Friedrich Wilhelms | VHH BINDING TO PLASMINE |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004045558A2 (en) | 2002-11-18 | 2004-06-03 | President And Fellows Of Harvard College | Compositions and methods for treating thrombotic disorders |
| EP2753359B1 (en) * | 2011-09-06 | 2018-02-28 | Translational Sciences Inc. | Serpinf2-binding molecules and methods of use |
| EP2948167A4 (en) | 2013-01-22 | 2016-10-19 | Univ Tennessee Res Foundation | TISSUE CLASMINE ACTIVATOR ANTIBODIES AND METHOD OF USE THEREOF |
| CN105612183A (zh) | 2013-07-15 | 2016-05-25 | 诺和诺德股份有限公司 | 结合尿激酶纤溶酶原激活物的抗体 |
-
2018
- 2018-09-21 EP EP18195872.9A patent/EP3459974B1/en active Active
- 2018-09-21 US US16/137,665 patent/US11066482B2/en active Active
- 2018-09-21 JP JP2018177525A patent/JP6971946B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020516240A5 (enExample) | ||
| JP2010536384A5 (enExample) | ||
| RU2014143785A (ru) | Фармацевтическая композиция для лечения и/или предотвращения рака печени | |
| HRP20191999T1 (hr) | Monoklonska protutijela anti-faktora xi i postupci njihove uporabe | |
| RU2014143784A (ru) | Фармацевтическая композиция для лечения и/или предотвращения рака желчного пузыря | |
| RU2010119521A (ru) | Антитела, связывающие il-4 и/или il-13, и их применение | |
| RU2014108047A (ru) | Фармацевтическая композиция для лечения и/или профилактики рака поджелудочной железы | |
| JP2017113019A5 (enExample) | ||
| JP2018502051A5 (enExample) | ||
| HRP20201733T1 (hr) | Postupci liječenja stanja povezanih s aktivacijom komplementa ovisnim o masp-2 | |
| RU2019118359A (ru) | Антитело к cd73 человека | |
| JP2014533239A5 (enExample) | ||
| EA032189B9 (ru) | Изолированные человеческие моноклональные антитела против ингибитора пути тканевого фактора (tfpi) и фармацевтическая композиция, содержащая их | |
| JP2020526478A5 (enExample) | ||
| JP2009518005A5 (enExample) | ||
| ME02371B (me) | Sastojci i postupci za dijagnstikovanje i tretman raka | |
| JP2018508483A5 (enExample) | ||
| JP2017536341A5 (enExample) | ||
| GEP20115324B (en) | Tweak binding antibodies | |
| JP2010516708A5 (enExample) | ||
| JP2018512124A5 (enExample) | ||
| JP2020502271A5 (enExample) | ||
| JP2018507220A5 (enExample) | ||
| JP2023015301A5 (enExample) | ||
| JP2016530223A5 (enExample) |